BERNA ENTERS PARTNERSHIPS WITH CSL, APOXIS

Berna Biotech AG said it has entered into two new partnerships, one with Australian group CSL and the other with Swiss company Apoxis SA. With CSL, the Swiss biotech group has signed an exclusive commercialisation and licence agreement to sell its Aerugen treatment in Australia and New Zealand. Aerugen is a vaccine for the prophylaxis of pseudomonas aeruginosa infections in cystic fibrosis patients and is expected to be launched in Europe in the year 2007.

Forbes (http://www.forbes.com/home/feeds/afx/2005/06/22/afx2105106.html)